License Agreement	9 Months Ended
	Sep. 30, 2023
License Agreement
License Agreement	License AgreementOn October 27, 2023, the Company provided written notice to ARIAD Pharmaceuticals, Inc. (“ARIAD”) of its termination of the License Agreement, dated June 13, 2018, between the Company and ARIAD (the “ARIAD License Agreement”), which termination will be effective in accordance with the terms of the termination for convenience clause of such agreement. The Company is not subject to any termination penalties related to the termination of the ARIAD License Agreement. For a summary of the terms of the ARIAD License Agreement including the Company’s accounting treatment, please refer to Note 7 to the Company’s audited consolidated financial statements for the year ended December 31, 2022, included in the Company’s Annual Report.